Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - With model applications for Denmark, Norway and Finland

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 4, 2010, Pages 474-480

  Hjalte, F ^a   Asseburg, C ^a   Tennvall, G R ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Atopic dermatitis; Cost effectiveness; Model simulation; Moisturizer; Nordic countries

Indexed keywords

BETAMETHASONE VALERATE; CANODERM; DERMATOLOGICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREAM; DENMARK; FINLAND; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NORWAY; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; SWEDEN;

BETAMETHASONE 17-VALERATE; COST-BENEFIT ANALYSIS; DENMARK; DERMATITIS, ATOPIC; EMOLLIENTS; FINLAND; GLUCOCORTICOIDS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; NORWAY; PRIMARY HEALTH CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SWEDEN;

EID: 77749302369     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03449.x     Document Type: Article

References (38)

1. Halvarsson K, Lodén M. Increasing quality of life by imrpoving the quality of skin in patients with atopic dermatitis. Int J Cosmet Sci 2007 29 : 69 83.
2. Bingefors K, Lindberg M, Isacson D. Self-reported dermatological problems and use of prescribed topical drugs correlate with decreased quality of life: an epidemiological survey. Br J Dermatol 2002 147 : 285 290.
3. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 141 : 1067 1075.
4. Isacson D, Bingefors K, Lindberg M. Self-reported dermatological problems and preferences for health: an epidemiological survey. Acta Derm Venereol 2004 84 : 27 31.
5. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and subjective measure of disease activity. Acta Derm Venereol 2000 80 : 430 434.
6. Schmitt J, Meurer M, Klon M et al. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2007 158 : 351 359.
7. Abramovits W, Boguniewicz M, Paller AS et al. The economics of topical immunomodulators for the treatment of atopic dermatitis. Pharmacoeconomics 2005 23 : 543 566. (Pubitemid 40994124)
8. Ellis CN, Drake LA, Prendergast MM et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 48 : 553 563.
9. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Exper Opin Pharmacother 2002 3 : 249 555.
10. Hoare C, LiWan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000 4 : 1 191.
11. Elias P, Wood L, Feingold K. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999 10 : 119 126.
12. Lucky A, Leach A, Laskarzewski P et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997 14 : 321 324.
13. Wiren K, Nohlgard C, Nyberg F et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009 doi :.
14. FASS. FASS 2008 (Pharmaceutical Specialties in Sweden). Läkemedelsindustriföreningen, Stockholm, 2008.
15. Southern Regional Health Care Board. Prices and Reimbursements for the Southern Health Care Region. Region Skåne, Lund, 2008.
16. Statistics Sweden (SCB). http://www.scb.se, 2008. (last accessed 19 September 2008).
17. Garside R, Stein K, Castlenuovo E et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 9 : iii, xi-xii, 1 230.
18. Hjelmgren J, Svensson Å, Jörgensen E et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on patient survey and clinical data. Br J Dermatol 2007 156 : 913 921.
19. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980 92 (Suppl. 44 47.
20. Van Leent EJ, Graber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998 134 : 805 809.
21. Andersson A-C, Lindberg M, Lodén M. The effect of two urea-containing creams on dry, eczematous skin in atopic patients. I. Expert, patients and instrumental evaluation. J Dermatolog Treat 1999 10 : 165 169. (Pubitemid 29438075)
22. The Swedish Medical Products Agency (MPA). Behandling av atopiskt eksem - Behandlingsrekommendation. Available at: http://www.lakemedelsverket.se/upload/ Hälso-%20och%20sjukvård/behandlingsrek/atopiskteksem.pdf, 2005 16)2 (last accessed 07 September 2009).
23. Den norske legeforening. Normaltariff for privat spesialistpraksis, http://www.legeforeningen.no/coccon/legeforeningen/normaltariff.xsp, 2008 (last accessed 12 November 2008).
24. Den norske legeforening. Fastlegetariffen-Normaltariff, http://www.legeforeningen.no/coccon/legeforeningen/normaltariff.xsp, 2008 (last accessed 12 November 2008).
25. Felleskatalogen. Felleskatalog over farmasøytiske spesialpreparater markedsført i Norge, http://www.felleskatalogen.no, 2008 (last accessed 06 November 2008).
26. Hujanen T, Kapiainen S, Tuominen U et al. Terveydenhuollon Yksikkökustannukset Suomessa Vuonna 2006. Helsinki : Stakes, 2008.
27. Medicin.dk. Dansk Lægemiddel Information A/S. http://www.medicin. dk, 2008 (last accessed 06 November 2008).
28. National Board of Taxes. Brief statistics 2008. http://www.vero.fi, 2008 (last accessed 12 November 2008).
29. Statistics Denmark. http://www.dst.dk, 2008 (last accessed 14 November 2008).
30. Statistics Norway. Lonnestatistik. http://www.ssb.no, 2008 (last accessed 14 November 2008).
31. Tohtori. http://www.tohtori.fi/, 2008 (last accessed 06 November 2008).
32. Persson U, Hjelmgren J. Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003 100 : 3436 3437.
33. LFN. General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board. Vol. LFNAR 2003:2. Stockholm : The Pharmaceutical Benefits Board, (Läkemedelsförmånsnämnden, LFN), 2003.
34. Chen CS, Bayoumi MA, Soon LS et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 2004 9 : 160 168.
35. McCombs K, Chen CS. Patients preference quality of life measures in dermatology. Dermatol Ther 2007 20 : 102 109.
36. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 2004 7 : 423 432.
37. Currie JC, McEwan P, Peters JR et al. The routine collation of health outcomes data from hospital treated subjects in the health outcomes data repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005 8 : 581 590.
38. Wildi MS, Cox HM, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004 99 : 1044 1049.